Groups HBV DNA (log IU/ml) eAg Seroconversion (%)
  Baseline 12 Wk 24 Wk 48 Wk Baseline 12 Wk 24 Wk 48 Wk
Mono-Therapy TM (n= 30) 6.26 ± 1.25 2.7± 1.3 1.82 ± 1.2 1.65 ± 0.69 - 13% 13% 13%
Sequential Therapy SQT(n=28) 6.61± 1.16 3.59 ± 1.4 2.1 3± 1.5 1.48 ± 0.9 - 13% 21% 21.40%
Table 2: eAg Seroconversion During Mono-Therapy and Sequential Therapy.